IE36995L - Producing attenuated viruses. - Google Patents

Producing attenuated viruses.

Info

Publication number
IE36995L
IE36995L IE721716A IE171672A IE36995L IE 36995 L IE36995 L IE 36995L IE 721716 A IE721716 A IE 721716A IE 171672 A IE171672 A IE 171672A IE 36995 L IE36995 L IE 36995L
Authority
IE
Ireland
Prior art keywords
virus
attenuated
cattle
dec
diluent
Prior art date
Application number
IE721716A
Other versions
IE36995B1 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IE36995L publication Critical patent/IE36995L/en
Publication of IE36995B1 publication Critical patent/IE36995B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16732Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761Methods of inactivation or attenuation
    • C12N2710/16764Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1356076 Attenuated virus vaccine; interferon induction BAYER AG 8 Dec 1972 [10 Dec 1971] 56723/72 Heading A5B A virus is attenuated by serial passage on tissue cultures until it will stimulate interferon production without producing specific immunity to the orginial virus. The virus may be I.P.V. virus (otherwise known as infectious pustular vulvovaginitis, Exanthema coitale vesiculosum bovis or cattle blister rash), pseudorabies virus or influenza virus. It may be passaged on calf kidney, suprarenal or testicular tissue. The attenuated virus may be compounded with a liquified gaseous diluent, isotonic fluid, a buffer solution, a liquid having a molecular weight of 200 or more or a solid diluent. The composition may be used as tablets, pills, dragees, capsules, ampoules for intramuscular injection or nasal sprays, or suppositories. They may be applied to cattle or pigs. [GB1356076A]
IE1716/72A 1971-12-10 1972-12-08 Improvements in and relating to attenuated viruses IE36995B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2161344A DE2161344C3 (en) 1971-12-10 1971-12-10 Production of virus strains which stimulate the natural defense mechanisms of a host organism without simultaneously having an antigenic effect and medicaments for the prophylaxis and treatment of viral and bacterial infections in humans and animals, containing such a virus strain

Publications (2)

Publication Number Publication Date
IE36995L true IE36995L (en) 1973-06-10
IE36995B1 IE36995B1 (en) 1977-04-13

Family

ID=5827622

Family Applications (1)

Application Number Title Priority Date Filing Date
IE1716/72A IE36995B1 (en) 1971-12-10 1972-12-08 Improvements in and relating to attenuated viruses

Country Status (22)

Country Link
JP (2) JPS6011013B2 (en)
AR (1) AR204075A1 (en)
AT (1) AT326817B (en)
AU (1) AU473209B2 (en)
BE (1) BE792484A (en)
BG (1) BG21417A3 (en)
CA (1) CA988848A (en)
CH (1) CH577558A5 (en)
CS (1) CS189587B2 (en)
DD (1) DD108115A5 (en)
DE (1) DE2161344C3 (en)
DK (1) DK143201C (en)
ES (1) ES409464A1 (en)
FR (1) FR2162637B1 (en)
GB (1) GB1356076A (en)
HU (1) HU167086B (en)
IE (1) IE36995B1 (en)
NL (1) NL178014C (en)
PH (1) PH12597A (en)
SE (1) SE8400283L (en)
SU (1) SU439956A3 (en)
ZA (1) ZA728709B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0063657A1 (en) * 1981-04-29 1982-11-03 Merck & Co. Inc. Topical application of interferon inducers

Also Published As

Publication number Publication date
JPS4862919A (en) 1973-09-01
DK143201B (en) 1981-07-20
DE2161344B2 (en) 1980-05-08
DE2161344C3 (en) 1986-10-02
JPS5924137B2 (en) 1984-06-07
DK143201C (en) 1981-12-14
SE8400283D0 (en) 1984-01-20
PH12597A (en) 1979-06-27
AU473209B2 (en) 1976-06-17
FR2162637B1 (en) 1976-07-02
SE8400283L (en) 1984-01-20
DE2161344A1 (en) 1973-06-20
ES409464A1 (en) 1976-03-16
ATA1041972A (en) 1975-03-15
JPS4862912A (en) 1973-09-01
NL7216628A (en) 1973-06-13
AT326817B (en) 1975-12-29
GB1356076A (en) 1974-06-12
JPS6011013B2 (en) 1985-03-22
AU4992072A (en) 1974-06-13
SU439956A3 (en) 1974-08-15
IE36995B1 (en) 1977-04-13
NL178014B (en) 1985-08-01
CA988848A (en) 1976-05-11
NL178014C (en) 1986-01-02
ZA728709B (en) 1973-08-29
BE792484A (en) 1973-06-08
DD108115A5 (en) 1974-09-05
CH577558A5 (en) 1976-07-15
FR2162637A1 (en) 1973-07-20
CS189587B2 (en) 1979-04-30
AR204075A1 (en) 1975-11-20
BG21417A3 (en) 1976-05-20
HU167086B (en) 1975-08-28

Similar Documents

Publication Publication Date Title
IE36995L (en) Producing attenuated viruses.
FR1512339A (en) Process for the preparation of ceramic products having a low coefficient of expansion
GB1169930A (en) Improvements in or relating to Lactam Salts
GB1159054A (en) Process for the preparation of Olefins
USD201181S (en) Ceiling panel
GB625646A (en) Improvements in or relating to processes for manufacturing mercaptans and the products thereof
USD140747S (en) Glass candle holder or article of similar nature
GB1413401A (en) Influenza vaccine
GB1390650A (en) Oxazines and thiazines
GB564828A (en) New vinyl compounds
GB657268A (en) Improvements in or relating to couplings for tubes and the like
GB942868A (en) Preparing triethylenediamine
USD144863S (en) Design for a radio receiver
FR1503745A (en) Device for suction, purification and evacuation of combustion products
GB1274032A (en) NOVEL 1-OXA-17alpha-METHYL-A-NOR-GONA-3,9-DIEN-2-ONES, PROCESSES FOR THEIR PREPARATION, AND COMPOSITIONS INCORPORATING THEM
GB1396754A (en) Process for preparing alpha-keto esters
Vengerovsky Osteomyelitis of the ilium in children
GB1228185A (en)
GB1330950A (en) Synthesis of 1,2-bis-p-carboxyphenoxy ethane
Reh et al. Possibilities of Calcining Aluminum Trihydrate in the Fluid Bed
Pindak Effect of statolon-induced interferon on antibody formation
FR1326925A (en) Process for separating the reaction products of water, boron trifluoride and an inorganic oxide modified by this trifluoride from a liquid hydrocarbon containing these products
ES248501A1 (en) A process for the electrothermal production of magnesium
JPS51138635A (en) Process for preparation of styrene oxide
FR2159048A5 (en) Isoprene polymerisation - to cis-14-polyisoprene using norbornadiene as mol wt controller